WoundCentrics, LLC, a comprehensive wound care company based in New Braunfels, Texas, has announced participation in 2 clinical trials at several of their Texas clinical sites. “As we have grown and our patient volumes and clinical research capabilities grew, we recognized the need to contribute to the body of evidence in wound care in order to better care for those we serve,” stated Marcus Gitterle, MD, WoundCentrics’ Chief Medical Officer. In making the commitment, the company hired a clinical research coordinator and invested in the infrastructure required to successfully manage the complexities of producing meaningful results from its work.
The first study, sponsored by Engineered Tissue Solutions (ETS), an emerging wound care device company that has developed an innovative bioactive glass technology that reduces healing time, minimizes treatment costs, and improves patient outcomes. This Phase Three Clinical Trial, which ETS has funded, utilizes ETS’ Mirragen Engineered Dermal Substitute for the treatment of Diabetic Foot Ulceration. WoundCentrics will support as a clinical trial site and has already begun enrolling patients in Corpus Christi, Texas.
Additionally, WoundCentrics is expected to serve as a primary site in a clinical trial sponsored by Estar Technologies, LTD, which will utilize their innovative Platelet Rich Fibrin product in the treatment of Diabetic Foot Ulcers. The clinical trial is currently awaiting final IRB approval and is expected to begin later this summer in multiple WoundCentrics locations in Texas.
While funded studies enable broader research objectives, WoundCentrics has also undertaken several retrospective studies which are ongoing in the areas of Chronic DVT and venous ulcer disease, as well as revascularization outcomes in patients recommended for amputation due to having been deemed to have “no other options.”
It is a privilege to be able to help advance the state of the art in Wound Care and to be able to offer leading-edge therapies to our patients. I’m proud of our team for their outstanding contributions in the area of clinical research,” remarked Dr. Gitterle.
Stuart Oertli, WoundCentrics’ Chief Operating Officer, closed by saying, “It is our goal to continue to grow our research capabilities, engage in new studies regularly and collaborate with our teams and sponsors to publish the findings our research is able to generate. Under the guidance of Dr. Gitterle and with the support of our Vice President of Ambulatory Services, Ben Simpson, we have already seen early success both for our patients and our research partners.”